Navigation Links
Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger
Date:12/4/2008

icalRecords.com PHR is marketed as a private-label product to healthcare professionals and hospitals.

Current MMR customers include AFL-CIO unions, Alexian Brothers Hospital Network, Coverdell, MedicAlert, Midwest Research Institute, Qvisory, and XN Financial. MMR is also a Google Health Integrated Service Provider. The company has license agreements to sell its products in several other countries around the world.

After the merger closes, MMR plans a series of product development, marketing and technology initiatives, including the launch of its MMR physician product, MMR Pro. The MMR professional document management system is a low-cost alternative solution to an Electronic Medical Record ("EMR") system and is aimed at helping the approximately 90% of physicians in small practice groups still using paper records get both back-file and day forward electronic documentation. Where existing EMR systems can cost as much as $40,000 per physician just to set-up, MMR Pro is expected to be offered at a starting cost of $500 per month.

MMR further leverages its patent-pending technologies through the brand extension MyEsafeDepositBox.com. Based on the same architecture as the MyMedicalRecords.com PHR, the MyEsafeDepositBox.com service is targeted to consumers who recognize the need to keep all their important documents in addition to personal medical records securely online so they can access them anytime from anywhere, especially in emergencies or when traveling.

The company plans also to focus on promoting initiatives to U.S. Government Officials requesting that Health IT legislation involving Personal Health Records incorporates provisions that give consumers the ability to add their existing paper medical records to any electronic PHR. This will enable individuals to have immediate access to their personal health information in one convenient location regardless of the system being used b
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction
2. Favrille Announces Receipt of Nasdaq Letters
3. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
4. Favrille Announces Workforce Reduction
5. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
6. Favrille Reports First Quarter 2008 Financial Results
7. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille Announces $21.1 Million Registered Direct Offering
10. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
11. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... BEIJING , June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... and,sale of medical products in China , said today that it ... anesthesia product manufactured,by Penlon, a UK firm specializing in anesthesia and breathing ... , ...
... -- Pioneer Surgical Technology, Inc. is pleased to announce that the ... study patients was presented at the recent 10th annual meeting of The ... Orleans by Domagoj Coric , M.D., Chief, Department of Neurosurgery, ... , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... This news release is available in ... November 26, 2013 In the developing world, Cryptosporidium ... decade ago, it announced its presence in the United States, ... the county,s history. Its rapid ability to spread, combined with ...
... new study reveals how pollution causes thunderstorms to leave ... Proceedings of the National Academy of Sciences ... reveal how pollution plays into climate warming. The work ... weather and climate models. Researchers had thought that ...
... mild cognitive impairment is a transitional stage between ... networks during this transformation have yet to be ... University of Technology, China constructed brain networks using ... four populations (normal controls, patients with early mild ...
Cached Biology News:Treatment target identified for a public health risk parasite 2The lingering clouds 2The lingering clouds 3
... GenePix Pro is the industry standard ... unique combination of imaging and analysis tools, ... use. GenePix Pro is included with every ... images from third-party scanners and all types ...
... the one mouse-click image analysis software ... It is the solution for high ... images. MicroVigene is empowered with VigeneTechs ... grid, regional 2D-curve fitting background correction ...
... For applications not requiring confocal, the ... alternative to the Pathway 435. And, the ... if later applications require it. ... can elect to use the laser autofocus, ...
... Proteomic Imaging System, Professional Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
Biology Products: